SCHEMBL2704914

SCHEMBL2704914

CCOC(=O)c1nn(C)c2c1CN(S(=O)(=O)c1ccc(C)cc1)c1ccccc1-2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNN4 O15554 1/20 0.47
▸ KCNA3 P22001 1/20 0.47
▸ GABRG2 P18507 3/20 0.42
▸ GABRB3 P28472 3/20 0.42
▸ GABRA5 P31644 3/20 0.42
▸ GABRA2 P47869 2/20 0.42
▸ GABRB2 P47870 1/20 0.42
▸ CCNA2 P20248 2/20 0.42
▸ CDK2 P24941 2/20 0.42
▸ CCNA1 P78396 2/20 0.42
▸ CDK4 P11802 1/20 0.42
▸ CCND3 P30281 1/20 0.42
▸ CDK6 Q00534 1/20 0.42
▸ TP53 P04637 3/20 0.41
▸ POLB P06746 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ NOD2 Q9HC29 1/20 0.41
▸ NOD1 Q9Y239 1/20 0.41
▸ GABRA1 P14867 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2704763 0.87 CA9 (0.46) CCNA2CDK2CCNA1TP53KDM4E
SCHEMBL8136017 0.87 KCNN4 (0.52) KCNN4KCNA3CCNA2CDK2CCNA1
SCHEMBL2705290 0.85 CA9 (0.52) KCNN4KCNA3CCNA2CDK2CCNA1
SCHEMBL12240647 0.79 CCNA2 (0.47) GABRG2GABRB3GABRA5GABRA2GABRB2
SCHEMBL2705962 0.74 PSEN1 (0.53) KCNN4KCNA3POLBNOD2NOD1
SCHEMBL2704905 0.72 PSEN1 (0.48) KCNN4KCNA3TP53POLBGAA
SCHEMBL2702423 0.72 CCNA2 (0.51) KCNN4KCNA3CCNA2CDK2CCNA1
SCHEMBL12240664 0.71 CCNA2 (0.59) CCNA2CDK2CCNA1CDK4CCND3
SCHEMBL14502625 0.71 KCNN4 (0.55) KCNN4KCNA3GAANOD2NOD1
SCHEMBL1495972 0.71 KMT2A (0.47) KCNN4KCNA3TP53GAANOD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2450358-A1 Fused, tricyclic sulfonamide inhibitors of gamma secretase Elan Pharmaceuticals Inc. (US) 2012-05-09 — — EP claimed
EP-2038280-A2 FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE Elan Pharmaceuticals Inc. (US) 2009-03-25 — — EP claimed
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. 2008-01-24 — — US claimed
WO-2007143523-A2 FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2007-12-13 — — WO claimed
EP-2450358-A1 Fused, tricyclic sulfonamide inhibitors of gamma secretase Elan Pharmaceuticals Inc. (US) 2012-05-09 — — EP disclosed
EP-2038280-A2 FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE Elan Pharmaceuticals Inc. (US) 2009-03-25 — — EP disclosed
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. 2008-01-24 — — US disclosed
WO-2007143523-A2 FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2007-12-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase BACE1, BACE2, PSEN1 KCNN4 3516/4885KCNA3 2000/4885GABRG2 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback